Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
3.460
+0.090 (2.67%)
At close: Mar 6, 2026, 4:00 PM EST
3.450
-0.010 (-0.29%)
After-hours: Mar 6, 2026, 4:04 PM EST
Pluri Employees
As of June 30, 2025, Pluri had 142 total employees, including 127 full-time and 15 part-time employees. The number of employees increased by 24 or 20.34% compared to the previous year.
Employees
142
Change (1Y)
24
Growth (1Y)
20.34%
Revenue / Employee
$9,430
Profits / Employee
-$184,070
Market Cap
32.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Atara Biotherapeutics | 38 |
| PDS Biotechnology | 24 |
| INmune Bio | 22 |
| Tempest Therapeutics | 21 |
| ABVC BioPharma | 19 |
| Outlook Therapeutics | 17 |
| Rein Therapeutics | 11 |
PLUR News
- 2 months ago - Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - GlobeNewsWire
- 10 months ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 11 months ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 1 year ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 1 year ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 1 year ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 1 year ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 1 year ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire